Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,121 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

NCT01592370

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +18 more
Locations
  • Local Institution - 0035 Clovis, California, United States
  • Division Of Hematology & Oncology Ctr. For Health Sciences Los Angeles, California, United States
  • Local Institution - 0012 Los Angeles, California, United States
  • Local Institution - 0017 Aurora, Colorado, United States
View all 43 locations
View Trial Details
Completed

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

NCT03767257

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Diarrhea, +16 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (All Protocol Activities) Commack, New York, United States
View Trial Details
Completed

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

NCT02252172

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Birmingham, Alabama, United States
  • Mobile, Alabama, United States
  • Glendale, Arizona, United States
  • Berkeley, California, United States
View all 206 locations
View Trial Details
Completed

A Study in Adults With Untreated Acute Lymphoblastic Leukemia

NCT00136435

Conditions
Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • University Of Columbia Medical Center New York, United States
  • Manitoba Blood & Marrow Transplant Program CancerCare Manitoba Winnipeg, Manitoba, Canada
View Trial Details
Completed

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

NCT01711632

Conditions
Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Scripps Clinic La Jolla, California, United States
  • Northwestern University Evanston, Illinois, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Completed

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05105841

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +15 more
Locations
  • Duplicate_NHO Nagoya Medical Center /ID# 233523 Nagoya, Aichi-ken, Japan
  • Aichi Cancer Center Hospital /ID# 238797 Nagoya, Aichi-ken, Japan
  • Duplicate_Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 233524 Nagoya, Aichi-ken, Japan
  • Duplicate_Chiba Cancer Center /ID# 238839 Chiba, Japan
View all 20 locations
View Trial Details

Related conditions